Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATHANASDAQ:ENVBNASDAQ:EQNASDAQ:NERV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHAAthira Pharma$0.30-2.3%$0.29$0.22▼$3.67$12.10M3.031.58 million shs293,306 shsENVBEnveric Biosciences$1.27+0.8%$1.27$1.01▼$11.55$3.11M0.53771,524 shs101,067 shsEQEquillium$0.33+1.4%$0.40$0.31▼$1.50$11.52M1.94434,690 shs109,108 shsNERVMinerva Neurosciences$1.80-0.8%$1.66$1.15▼$3.50$12.66M-0.3723,551 shs2,323 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHAAthira Pharma-2.26%-0.33%+12.85%-8.76%-88.35%ENVBEnveric Biosciences+0.79%+4.96%+2.83%-27.01%-87.38%EQEquillium+1.36%-5.79%-15.11%-57.71%-52.62%NERVMinerva Neurosciences+0.22%-1.64%+23.79%-0.28%-48.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATHAAthira Pharma2.3066 of 5 stars3.03.00.00.00.62.51.3ENVBEnveric Biosciences1.553 of 5 stars3.52.00.00.00.00.01.3EQEquillium2.436 of 5 stars3.25.00.00.00.61.70.6NERVMinerva Neurosciences3.4575 of 5 stars3.03.00.04.60.00.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATHAAthira Pharma 2.00Hold$11.253,612.87% UpsideENVBEnveric Biosciences 3.00Buy$10.00687.40% UpsideEQEquillium 2.33Hold$3.00817.71% UpsideNERVMinerva Neurosciences 2.00Hold$5.00178.55% UpsideCurrent Analyst Ratings BreakdownLatest ENVB, ATHA, NERV, and EQ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2025EQEquilliumLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/28/2025EQEquilliumLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$3.00 ➝ $1.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATHAAthira PharmaN/AN/AN/AN/A$1.16 per shareN/AENVBEnveric BiosciencesN/AN/AN/AN/A$2.35 per shareN/AEQEquillium$41.10M0.28N/AN/A$0.54 per share0.61NERVMinerva NeurosciencesN/AN/A$0.21 per share8.66($3.67) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATHAAthira Pharma-$96.94M-$2.07N/AN/AN/AN/A-142.99%-106.40%7/30/2025 (Estimated)ENVBEnveric Biosciences-$9.57M-$38.38N/AN/AN/AN/A-250.28%-195.57%8/11/2025 (Estimated)EQEquillium-$8.07M-$0.39N/AN/AN/A-19.62%-74.34%-46.75%8/6/2025 (Estimated)NERVMinerva Neurosciences$1.44M$0.822.19N/AN/AN/A-20.68%15.73%8/5/2025 (Estimated)Latest ENVB, ATHA, NERV, and EQ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ENVBEnveric Biosciences-$3.45-$1.22+$2.23-$1.22N/AN/A5/13/2025Q1 2025NERVMinerva Neurosciences-$1.07-$0.50+$0.57-$0.50N/AN/A5/9/2025Q1 2025ATHAAthira Pharma-$0.20-$0.23-$0.03-$0.23N/AN/A3/27/2025Q4 2024EQEquillium-$0.22-$0.16+$0.06-$0.16N/A$4.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATHAAthira PharmaN/AN/AN/AN/AN/AENVBEnveric BiosciencesN/AN/AN/AN/AN/AEQEquilliumN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATHAAthira PharmaN/A7.267.26ENVBEnveric BiosciencesN/A4.084.08EQEquilliumN/A2.702.70NERVMinerva NeurosciencesN/A9.219.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATHAAthira Pharma57.12%ENVBEnveric Biosciences13.82%EQEquillium27.05%NERVMinerva Neurosciences34.56%Insider OwnershipCompanyInsider OwnershipATHAAthira Pharma22.10%ENVBEnveric Biosciences1.10%EQEquillium31.60%NERVMinerva Neurosciences8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATHAAthira Pharma4039.04 million30.41 millionOptionableENVBEnveric Biosciences202.47 million2.45 millionNot OptionableEQEquillium4035.72 million24.43 millionNot OptionableNERVMinerva Neurosciences96.99 million6.39 millionNot OptionableENVB, ATHA, NERV, and EQ HeadlinesRecent News About These CompaniesMinerva Neurosciences (NASDAQ:NERV) Stock Price Crosses Below 200 Day Moving Average - Here's WhyJune 20 at 4:11 AM | americanbankingnews.comNordic Capital invests in CRO and CDMO Minerva ImagingJune 11, 2025 | pehub.comMinerva Neurosciences, Inc: Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business UpdatesMay 14, 2025 | finanznachrichten.deMinerva Neurosciences Reports First Quarter 2025 Financial Results and Business UpdatesMay 13, 2025 | globenewswire.comMinerva Neurosciences Inc.April 23, 2025 | barrons.comMinerva Neurosciences regains Nasdaq complianceMarch 21, 2025 | investing.comMinerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business UpdatesFebruary 25, 2025 | globenewswire.comMinerva Neurosciences stock hits 52-week low at $2.02February 12, 2025 | msn.comMinerva Neurosciences Stock Hits 52-Week Low at $2.03January 22, 2025 | msn.comMinerva Neurosciences Reports Third Quarter 2024 Financial Results and Business UpdatesNovember 6, 2024 | markets.businessinsider.comMinerva Neurosciences Reports Third Quarter 2024 Financial Results and Business UpdatesNovember 5, 2024 | globenewswire.com'It has meant everything': Minerva girls win second straight cross country state titleNovember 4, 2024 | msn.comMinerva Fabienne Hase and Nikita Volodin of Germany sit in top spot after pairs shortNovember 2, 2024 | msn.comUS to Overtake China as Top Beef Importer From Brazil’s MinervaNovember 1, 2024 | bloomberg.comCommunity Conversations: El Paso Sheriff candidate Minerva Torres SheltonOctober 30, 2024 | msn.comNeuroscientist, Musician, and Author Dr. Daniel Levitin Talks New Book ‘I Heard There Was a Secret Chord: Music as Medicine’ and More (INTERVIEW)October 28, 2024 | glidemagazine.comPotential ingredient to prevent hyperpigmentation after being treated for varicose veinsOctober 28, 2024 | labroots.comMinerva chamber member honored as 'Bright Star'October 28, 2024 | yahoo.comHigh school cross country: Minerva sweeps boys and girls district titles againOctober 21, 2024 | msn.comCross country or soccer? Minerva's Tateum Richard decided on both and she excels in eachOctober 19, 2024 | cantonrep.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeENVB, ATHA, NERV, and EQ Company DescriptionsAthira Pharma NASDAQ:ATHA$0.30 -0.01 (-2.26%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.31 +0.00 (+1.32%) As of 06/20/2025 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.Enveric Biosciences NASDAQ:ENVB$1.27 +0.01 (+0.79%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.27 0.00 (-0.31%) As of 06/20/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.Equillium NASDAQ:EQ$0.33 +0.00 (+1.36%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.32 -0.01 (-2.11%) As of 06/20/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.Minerva Neurosciences NASDAQ:NERV$1.80 -0.02 (-0.83%) Closing price 06/20/2025 03:48 PM EasternExtended Trading$1.73 -0.06 (-3.62%) As of 06/20/2025 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
